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Introduction
Metformin is first-line therapy for people with type 2 dia-
betes. Due to potential lactic acidosis it is contraindicated
in patients with estimated glomerular filtration rate
(eGFR) < 60 mL/min/1.73m2, although little is known
about its use among patients with chronic kidney disease
(CKD). The objective of this study was to determine the
association between kidney function and mortality among
incident metformin users.
Methods
Databases of the Alberta Kidney Disease Network (http://
www.akdn.info; Alberta, Canada) were used to identify a
cohort aged 66 and older with diabetes who were incident
metformin users from November 1, 2002 until March 31,
2008. The cohort was stratified on frequency of creatinine
measurements prior to initiating metformin: none; a pre
measurement only (6 months prior to metformin initia-
tion); a post measurement only (within 1 year after); and
both pre and post measurements. Patients were categor-
ized by stage of CKD: 1 & 2 ( ≥ 60 mL/min/1.73m2; refer-
ence); 3a (45 - 59 mL/min/1.73m2); 3b (30 -44 mL/min/
1.73m2); 4 & 5 (< 30 mL/min/1.73m2); and no measure-
ments. A Cox proportional hazards model was used to
determine the association between kidney function and
mortality, controlling for demographics, Charlson morbid-
ity scores, hypertension, and visits to general practitioners.
Results
Of the 22,051 new users of metformin, 1,766 (8.0%) did
not have a creatinine measurement before or after metfor-
min initiation. Baseline characteristics were similar across
groups stratified by frequency of creatinine measurements.
A larger proportion of patients who had no creatinine
measurements were rural-residing (31.3%) compared to
those with pre (17.5%), post (21.1%) and both (15.8%)
measurements. Of the subset with a measured eGFR, 25%
of incident metformin users had eGFR <60ml/min. There
was a small significant increase in the risk of mortality in
incident metformin users with CKD stage 3b only (HR:
1.15 ; 95% CI: 1.04-1.28) compared to people with an
eGFR of ≥60 mL/min/1.73m2.
Conclusions
Metformin was commonly prescribed to patients with
decreased kidney function, and did not appear to be
associated with an increased risk of death.
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